1YBetter than half the group
Rank 23 of 63 funds
Return +20.15%
1Y returns of 63 funds in the Health Care group, sorted from highest to lowest. This fund ranks 23No. 1 is SCBGENOME(E) +62.13%
KTAM World Healthcare Fund
Shows where this fund stands in its group. Not investment advice · Data as of 3 Nov 2026
KT-HEALTHCARE-SSF invests through the master fund Janus Henderson Global Life Sciences Fund 99.65%
This fundKT-HEALTHCARE-SSF
The fund that actually investsJanus Henderson Global Life Sciences FundThis fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Eli Lilly and Co LLY9.58%
Johnson & Johnson JNJ7.75%Data as of 30 Sep 2026 · Top 6 shown, the rest grouped as Other · per Janus Henderson fact sheet
Over the past year it beat half its group; over 3 years it returned +12.16% per year (Top 25% of the group)
No. 1 is SCBGENOME(E) +62.13%
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 3 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | 3Y | MAX |
|---|---|---|---|---|---|---|---|---|
| +11.75% | +2.43% | +2.67% | +7.57% | +5.67% | +15.11% | +20.15% | +41.08% | +28.60% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan | Feb | Mar |
|---|
Largest drawdown in the selected period −22.90% Previous peak 30 Aug 2024 (NAV 16.9583) → Trough 14 May 2025 (NAV 13.0747) · Back to the previous peak on 25 Nov 2025, after 6 months
Currently −1.88% from the peak NAV of 19.2196 (19 Aug 2026)
Over 3 years, KT-HEALTHCARE-SSF returned 0.72 per unit of volatility, ranking 6 of 37 funds · The highest is TBIOTECH (0.88)
กองทุนเน้นลงทุนในหน่วยลงทุนของกองทุน Janus Henderson Global Life Sciences Fund (Master Fund) เพียงกองเดียว โดยเฉลี่ยในรอบปีบัญชี ไม่น้อยกว่าร้อยละ 80 ของมูลค่าทรัพย์สินสุทธิของกองทุนรวม หรือตามอัตราส่วนที่สำนักงานคณะกรรมการ ก.ล.ต. จะประกาศกำหนด โดยกองทุน Janus Henderson Global Life Sciences Fund… Its largest holdings are หน่วยลงทุน Janus Global Life Sciences Fund 99.39% (fact sheet 30 Sep 2026)
Risk level 7 of 8 (High risk). Since 25 Nov 2022, its NAV has fallen as much as −22.90% from its peak.
Actual total expense ratio (TER) 1.34% a year, against a ceiling of 5.35%. Management fee 1.34%. Front-end fee 0.00%. Back-end fee 0.00%. (Fact sheet 31 Aug 2026)
It has a dividend policy but has not paid any dividends yet
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Unitedhealth Group UNH4.26%
AstraZeneca AZN.L3.70%
Thermo Fisher TMO3.34%
Novartis NOVN2.72%
Roche ROG2.67%
argenx ARGX2.44%
Merck & MRK2.34%Eli Lilly and Co LLYDiabetes and weight-loss drugs
An American medicines and medical devices company, with products such as cancer drugs and surgical instruments
ABBVIE ABBVHospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
AstraZeneca AZN.LHospitals, medicines and medical equipment
Thermo Fisher TMOAn American company selling scientific instruments, reagents and services for laboratories
Novartis NOVNHospitals, medicines and medical equipment
Roche ROGHospitals, medicines and medical equipment
argenx ARGXEuropean biotech that makes Vyvgart to treat autoimmune diseases such as myasthenia gravis
Merck & MRKHospitals, medicines and medical equipment
Based on the master fund's share of this fund's value (99.65% as of 31 Aug 2026) × each stock's weight in the master fund · stocks as of 30 Sep 2026 · fact sheet from Janus Henderson · Illustrations are for explanation only, not individual stock recommendations
No. 1 is SCBGENOME(E) +21.97% per year
| Apr |
|---|
| May |
|---|
| Jun |
|---|
| Jul |
|---|
| Aug |
|---|
| Sep |
|---|
| Oct |
|---|
| Nov |
|---|
| Dec |
|---|
| Full year |
|---|
| 2026 | +0.0 | +1.4 | −5.5 | +1.2 | +1.8 | +8.4 | −0.7 | +3.2 | −4.1 | +6.7 | −0.5 | · | +11.7* |
| 2025 | +5.4 | +0.1 | −4.0 | −2.3 | −6.7 | +1.6 | −0.9 | +5.4 | +2.2 | +8.3 | +8.7 | −1.4 | +16.0 |
| 2024 | +2.7 | +3.8 | +1.5 | −4.7 | +3.0 | +2.8 | +1.7 | +3.4 | −3.4 | −2.5 | −1.0 | −8.0 | −1.6 |
| 2023 | −0.7 | −4.1 | +1.6 | +3.6 | −2.7 | +2.8 | −0.2 | −1.6 | −3.5 | −7.1 | +6.5 | +6.7 | +0.3 |
| 2022 | · | · | · | · | · | · | · | · | · | · | +2.2 | −1.6 | +0.5* |
Minimum first purchase not set, subsequent purchases not set. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+4
Varies by share class. As of 30 Sep 2026, 68.69% of the value of its foreign investments was hedged
They are share classes of the same fund and invest in the same assets. They differ only in each class's terms, such as dividend policy, fees or who can buy · KT-HEALTHCARE-SSF: pays dividends, TER 1.34% · KT-HEALTHCARE-A: no dividends, TER 1.34% · KT-HEALTHCARE-D: see the conditions in the prospectus · KT-HEALTHCARE-I: see the conditions in the prospectus · KT-HEALTHCARE-P: see the conditions in the prospectus · KT-HEALTHCARE-R: see the conditions in the prospectus · KT-HEALTHCARE-UHA: see the conditions in the prospectus · KT-HEALTHCARE-USD-A: no dividends, TER 0.00%